Altimmune draws retail buzz ahead of key 48-week MASH data
Altimmune gained heavy retail attention as investors count down to 48-week Phase 2b data for pemvidutide in MASH. Traders pointed to AI-assisted biopsy findings and clearer dose-response evidence, while analysts remain split over differentiation and funding risk. A recent Lancet publication and AASLD late-breaker added momentum as Altimmune advances more liver programs toward 2026 readouts.